The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Published version of a preprint
Abstract
KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their dependence on mutant KRAS. However, analysis of the remaining cell population after long-term Cas9 expression unmasked the occurence of oncogenic KRAS escape variants that were resistant to Cas9-cleavage. In contrast, the use of an adenine base editor to correct oncogenic KRAS mutations progressively depleted the targeted cells without the appearance of escape variants and allowed efficient and simultaneous correction of a cancer-associated TP53 mutation. Oncogenic KRAS and TP53 base editing was possible in patient-derived cancer organoids, suggesting that base editor approaches to correct oncogenic mutations could be developed for functional interrogation of vulnerabilities in a personalized manner for future precision oncology applications. Significance: Repairing KRAS mutations with base editors can be used for providing a better understanding of RAS biology and may lay the foundation for improved treatments for KRAS-mutant cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to the CRISPR–Cas9 vector, the CRISPR adenine base-editing system not only possibly eliminates targeted cells but also effectively corrects tumor-associated TP53 mutations.419”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [419]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Engineered CRISPR-Cas9 nuclease with expanded targeting space
Nishimasu, H., Shi, X., Ishiguro, S., Gao, L., Hirano, S., Okazaki, S., Noda, T., Abudayyeh, O. O., Gootenberg, J. S., Mori, H., et al. (2018) · Science · doi:10.1126/science.aas9129 · Cited by 1,100
Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0453-z · Cited by 1,020 · cited 5×
“5B ), echoing previous reports that ABEs are rather speci fi c (33).”
InfluentialIn vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03534-y · Cited by 793
Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668
Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019) · Nature · doi:10.1038/s41586-019-1161-z · Cited by 663
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Research works printed but not linked: 41
- Christensen, 2020, Targeting Kras g12c-mutant cancer with a mutation-specific inhibitor, J Intern Med, 288, 183, 10.1111/joim.13057 · DOI
- Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
- Bäumer, 2015, Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer, Clin Cancer Res, 21, 1383, 10.1158/1078-0432.CCR-13-2017 · DOI
- Gebler, 2017, Inactivation of cancer mutations utilizing CRISPR/Cas9, J Natl Cancer Inst, 109, 1546, 10.1093/jnci/djw183 · DOI
- Li, 2020, Programmable base editing of mutated TERT promoter inhibits brain tumour growth, Nat Cell Biol, 22, 282, 10.1038/s41556-020-0471-6 · DOI
- Chen, 2013, Dynamic imaging of genomic Loci in living human cells by an optimized CRISPR/Cas system, Cell, 155, 1479, 10.1016/j.cell.2013.12.001 · DOI · Paper page
- Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat Protoc, 8, 2281, 10.1038/nprot.2013.143 · DOI · Paper page
- Zafra, 2018, Optimized base editors enable efficient editing in cells, organoids and mice, Nat Biotechnol, 36, 888, 10.1038/nbt.4194 · DOI · Paper page
- Sayed, 2019, CRISPR/Cas9 as a tool to dissect cancer mutations, Methods, 164–165, 36, 10.1016/j.ymeth.2019.05.007 · DOI
- Hennig, 2019, CFTR Expression analysis for subtyping of human pancreatic cancer organoids, Stem Cells Int, 2019, 1
- Seidlitz, 2019, Human gastric cancer modelling using organoids, Gut, 68, 207, 10.1136/gutjnl-2017-314549 · DOI · Paper page
- Kluesner, 2018, EditR: a method to quantify base editing from sanger sequencing, CRISPR J, 1, 239, 10.1089/crispr.2018.0014 · DOI · Paper page
- Clement, 2019, CRISPResso2 provides accurate and rapid genome editing sequence analysis, Nat Biotechnol, 37, 224, 10.1038/s41587-019-0032-3 · DOI · Paper page
- Li, 2018, Minimap2: pairwise alignment for nucleotide sequences, Bioinformatics, 34, 3094, 10.1093/bioinformatics/bty191 · DOI · Paper page
- Lawrence, 2013, Software for computing and annotating genomic ranges, PLoS Comput Biol, 9, e1003118EP, 10.1371/journal.pcbi.1003118 · DOI · Paper page
- Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
- Picardi, 2013, REDItools: high-throughput RNA editing detection made easy, Bioinformatics, 29, 1813, 10.1093/bioinformatics/btt287 · DOI · Paper page
- Rees, 2018, Base editing: precision chemistry on the genome and transcriptome of living cells, Nat Rev Genet, 19, 770, 10.1038/s41576-018-0059-1 · DOI · Paper page
- Pruitt, 2000, Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells, J Biol Chem, 275, 40916, 10.1074/jbc.M006682200 · DOI
- Agbunag, 2004, Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells, Cancer Res, 64, 5659, 10.1158/0008-5472.CAN-04-0807 · DOI
- Fan, 1997, K-ras modulates the cell cycle via both positive and negative regulatory pathways, Oncogene, 4, 2595, 10.1038/sj.onc.1201105 · DOI
- Xin, 2019, Off-Targeting of Base Editors: BE3 but not ABE induces substantial off-target single nucleotide variants, Signal Transduct Target Ther, 4, 9, 10.1038/s41392-019-0044-y · DOI
- Kastenhuber, 2017, Putting p53 in context, Cell, 170, 1062, 10.1016/j.cell.2017.08.028 · DOI · Paper page
- Hu, 2021, Targeting mutant p53 for cancer therapy: direct and indirect strategies, J Hematol Oncol, 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
- Steckel, 2012, Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies, Cell Res, 22, 1227, 10.1038/cr.2012.82 · DOI · Paper page
- Dwane, 2020, Project score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets, Nucleic Acids Res, 6, 38
- Kim, 2018, Targeting mutant KRASwith CRISPR-Cas9 controls tumor growth, Genome Res, 28, 374, 10.1101/gr.223891.117 · DOI · Paper page
- Arbab, 2020, Determinants of base editing outcomes from target library analysis and machine learning, Cell, 182, 643, 10.1016/j.cell.2020.05.037 · DOI · Paper page
- Chu, 2021, Rationally designed base editors for precise editing of the sickle cell disease mutation, CRISPR J, 4, 169, 10.1089/crispr.2020.0144 · DOI
- Tan, 2019, Engineering of high-precision base editors for site-specific single nucleotide replacement, Nat Commun, 10, 439, 10.1038/s41467-018-08034-8 · DOI · Paper page
- Grünewald, 2019, CRISPR DNA base editors with reduced RNA off-target and self-editing activities, Nat Biotechnol, 37, 1041, 10.1038/s41587-019-0236-6 · DOI · Paper page
- Kerk, 2021, Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment, Nat Rev Cancer, 21, 510, 10.1038/s41568-021-00375-9 · DOI · Paper page
- Pupo, 2019, KRAS-Driven metabolic rewiring reveals novel actionable targets in cancer, Front Oncol, 9, 848, 10.3389/fonc.2019.00848 · DOI
- Kamphorst, 2015, Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein, Cancer Res, 75, 544, 10.1158/0008-5472.CAN-14-2211 · DOI · Paper page
- Gradiz, 2016, MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors, Sci Rep, 6, 21648, 10.1038/srep21648 · DOI · Paper page
- Salgia, 2021, The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC), Cell Rep Med, 2, 100186, 10.1016/j.xcrm.2020.100186 · DOI · Paper page
- Ndlovu, 2018, Fibroblast growth factor 10 in pancreas development and pancreatic cancer, Front Genet, 9, 482, 10.3389/fgene.2018.00482 · DOI
- Levy, 2020, Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses, Nat Biomed Eng, 4, 97, 10.1038/s41551-019-0501-5 · DOI · Paper page
- Zeng, 2020, Therapeutic base editing of human hematopoietic stem cells, Nat Med, 26, 535, 10.1038/s41591-020-0790-y · DOI · Paper page
- Lim, 2022, Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases, Nat Commun, 13, 366, 10.1038/s41467-022-27962-0 · DOI
- Xu, 2021, Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing, Mol Cell, 81, 4333, 10.1016/j.molcel.2021.08.008 · DOI · Paper page
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Cortés Vesga, C. P., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., & Buchholz, F.
- Venue
- Cancer Research
- Published
- 2022-07-08
- Volume
- 82
- Issue
- 17
- Pages
- 3002-3015
- ISSN
- 0008-5472
- 1538-7445
- Cited by
- 46
- References
- 16
- Language
- en
- Funders
- European commission H2020 (825825)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-2519
- The paper
- Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Cortés Vesga, C. P., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., & Buchholz, F. (2022). Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-2519
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.